Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,088 across all filing types
Latest filing 2024-06-26 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于与施维雅达成伴随诊断合作的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a collaboration agreement between the company and another party for companion diagnostic cooperation. It details the nature of the agreement, the parties involved, and the expected impact on the company. There are no financial statements, no regulatory filings like 10-K or interim reports, no voting results, no management changes, and no mention of earnings or audit reports. The document is relatively short (1379 characters) and serves as a corporate announcement about a business cooperation agreement. This fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous corporate announcements that do not fit other specific categories.
2024-06-26 Chinese
关于公司获得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of a medical device registration certificate issued by a national regulatory authority. It describes the product details, registration certificate specifics, and the potential impact on the company. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting or voting results. The document is a regulatory announcement about a product certification, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2024-06-12 Chinese
关于披露简式权益变动报告书的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a disclosure announcement regarding a change in shareholding percentage of a shareholder (Xiamen Keying Investment Partnership) due to share repurchase and cancellation of restricted shares. It details the passive increase in shareholding percentage above 5%, making the shareholder a major shareholder. The document references relevant securities laws and confirms no change in control or governance structure. It is a notification of a significant shareholding change, not a full report or financial statement. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, confirming this classification.
2024-06-03 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding percentage of a specific shareholder (厦门科英投资合伙企业) in the company 厦门艾德生物医药科技股份有限公司. The document includes information about the shareholder, the nature of the shareholding change (passive increase due to share buybacks and cancellations), and confirms that the shareholder's holding has crossed the 5% threshold. It references relevant securities laws and disclosure regulations in China. The content is focused on notifying the market and regulators about a change in major shareholding levels rather than financial results, management changes, or other corporate events. This fits the definition of a Major Shareholding Notification (MRQ). The document length (5800 characters) and detailed disclosure also support this classification rather than a brief announcement or a regulatory filing fallback. Therefore, the appropriate classification is MRQ with high confidence.
2024-06-03 Chinese
关于回购股份进展的公告
Transaction in Own Shares Classification · 95% confidence The document is a public announcement from a company about the progress of its share repurchase program. It details the number of shares repurchased, the price range, total amount spent, and compliance with regulatory guidelines. The document does not contain financial statements or detailed financial analysis but reports on the status of a share buyback plan. It is not an annual or interim report, nor an earnings release or management discussion. It fits the category of a report on transactions in the company's own shares (share repurchase). Therefore, the appropriate classification is 'Transaction in Own Shares' (POS). The document length is short and focused solely on the buyback progress, confirming this classification with high confidence.
2024-06-03 Chinese
2023年度权益分派实施的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement regarding the implementation of the 2023 annual dividend distribution plan approved at the 2023 Annual General Meeting. It details the dividend amount, record date, ex-dividend date, and related procedural information. The document is relatively short (2480 characters) and primarily serves to inform shareholders about the dividend payment and related corporate actions. It does not contain full financial statements or comprehensive financial performance data. Therefore, it is not an Annual Report (10-K) or Interim Report (IR). It is also not a Notice of Dividend Amount (DIV) because it includes detailed implementation information and references the shareholder meeting approval, but the primary focus is on the dividend distribution implementation. Given the nature and length, this fits best as a Declaration of Voting Results & Voting Rights Announcements (DVA) because it reports the outcome of the shareholder vote on the dividend distribution and the implementation details. Confidence is high due to the clear focus on dividend distribution following shareholder approval.
2024-05-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.